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1 These authors contributed equally to this work.The putative CCDC106 protein was previously identiﬁed as a p53-interacting partner by automated
yeast two-hybrid screening, but its sequence and function have not been validated experimentally.
Here, we identiﬁed three variant transcripts of the CCDC106 gene; these transcripts differ in their
second exons due to the use of different splice acceptor site, but encode an identical protein of
280 residues. A bipartite nuclear localisation signal at residues 151–164 mediates the nuclear local-
isation of CCDC106. Double immunoﬂuorescence staining revealed the colocalisation of endogenous
CCDC106 and p53 protein in nuclei. The in vivo interaction between CCDC106 and p53 was con-
ﬁrmed by a co-immunoprecipitation assay. Furthermore, we demonstrated that CCDC106 promotes
the degradation of p53 protein and inhibits its transactivity.
Structured summary:
MINT-7681390: CCDC106 (uniprotkb:Q9BWC9) physically interacts (MI:0915) with p53 (uni-
protkb:P04637) by anti tag co-immunoprecipitation (MI:0007)
MINT-7681212: p53 (uniprotkb:P04637) and CCDC106 (uniprotkb:Q9BWC9) colocalise (MI:0403) by ﬂuo-
rescence microscopy (MI:0416)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The tumour suppressor protein p53 maintains genomic integ-
rity and cellular homeostasis. In response to stress signals such as
DNA damage, oncogenic stimuli or hypoxia, p53 accumulates in
the cell and becomes activated. It then initiates an anti-prolifera-
tion and pro-apoptotic program that prevents the multiplication
of damaged and potentially pre-cancerous cells [1,2]. Lack of
p53 function is often connected with development of cancer [3].
Inactivation of p53 by mutation occurs in over 50% of all human
cancers [4,5]. In cancer types that harbour wild-type p53, p53
function is frequently abolished by overexpression of negative
regulators such as MDM2 (mouse double minute 2) [6,7].
MDM2 is an important regulator of p53. It catalyses p53 ubiqui-
tination, marking p53 for degradation by the proteasome [8,9].
Apart from MDM2, p53 can be ubiquitinated by several other
ubiquitin ligases, such as COP1 (constitutively photomorphogenicchemical Societies. Published by E
).1), PirH2 (p53-induced RING-H2 protein) and synoviolin [10–13].
The stability of p53 is also controlled by physical interactions
with other proteins. Although these interacting proteins cannot
modify p53 themselves, they can impinge on p53 modiﬁcations
by enhancing or reducing the association of p53 with modifying
enzymes [13]. For example, some p53-interacting partners such
as ING1b and activating transcription factor 3 (ATF3) disrupt
the interaction between MDM2 and p53 and thus reduce p53
ubiquitination [13–15]. Other interacting partners, such as Yin
Yang 1 (YY1) and focal adhesion kinase (FAK), increase p53 ubiq-
uitination and degradation by stabilizing the interaction
[13,16,17]. These results suggest that identiﬁcation of novel inter-
acting partners of p53 will provide further insight into the regu-
lation of p53 activity.
The putative coiled coil domain containing 106 protein
(CCDC106, previously termed HSU79303 [18]) was identiﬁed as
a p53-interacting partner by automated yeast two-hybrid screen-
ing [18], but its sequence and interaction with p53 have not
been further conﬁrmed. Furthermore, the cellular function gener-
ated by the interaction between CCDC106 and p53 is unknown.
In this paper, we identiﬁed three variant transcripts of the
CCDC106 gene in HeLa cells and a bipartite nuclear localisationlsevier B.V. All rights reserved.
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CCDC106 interacts with p53 in vivo and promotes the degrada-
tion of the p53 protein.2. Materials and methods
2.1. Plasmids construction
The coding sequence of human CCDC106 was ampliﬁed with
primers ORF-EcoRI-F and ORF-KpnI-R (Table 1) and cloned into
pCMV-Myc and pEGFP-C3 at EcoRI and KpnI sites, resulting in
CCDC106 fusion protein expression plasmids pMyc-CCDC106 and
pEGFP-CCDC106. For generating the NLS (residues 151–164) dele-
tion mutant pEGFP-DNLS, the N-terminus (residues 1–150) and C-
terminus (residues 165–280) of CCDC106 were ampliﬁed from
pEGFP-CCDC106 (primers for N-terminal PCR: ORF-EcoRI-F and
NLSdel-R, primers for C-terminal PCR: NLSdel-F and ORF-KpnI-R;
NLSdel-F and NLSdel-R contain complementary overhangs), fol-
lowed by annealing and second ampliﬁcation with primers ORF-
EcoRI-F and ORF-KpnI-R. The ﬁnal PCR products were then cloned
into the EcoRI and KpnI sites of pEGFP-C3. The site-speciﬁc NLS mu-
tant plasmids pEGFP-mutNLS1(151RRR? 151AAA), pEGFP-mut-
NLS2(162RRR? 162AAA) and pEGRP-mutNLS(151RRR. . .162RRR?
151AAA. . .162AAA) were generated by overlapping extension PCR
as previously described [19]. The coding sequence of p53 was
cloned into pCMV-HA to generate the HA-tagged p53 expression
plasmid pHA-p53. The luciferase reporter plasmid pp53-TA-Luc
containing the p53 response element was purchased from BD Bio-
sciences Clontech (Palo Alto, CA, USA).
2.2. Cloning the full-length cDNA of CCDC106 by RLM-RACE
The putative coding sequence of CCDC106 was ampliﬁed
from HeLa ﬁrst-strand cDNA using primers ORF-F and ORF-R
(Table 1), and the ampliﬁed fragment was cloned into pMD18-
T vector (TaKaRa, Dalian, China) and sequenced. Based on the
coding sequence, gene-speciﬁc primers were designed to clone
the 50-end and 30-end sequences using the Firstchoice RLM-RACE
kit (Ambion) according to the manufacturer’s instructions.
Brieﬂy, ﬁrst-strand RACE-ready cDNA was synthesized with total
RNA extracted from HeLa cells. Subsequently, RACE-PCR and
nested RACE-PCR were performed with gene-speciﬁc primers
(Table 1) and universal primers provided in the kit. The ﬁnal
PCR products were cloned into the pMD18-T vector and
sequenced.Table 1
Primers used in this study.
Name Sequence (50–30)
ORF-EcoRI-Fa GAATTCCCATGAATGACCGGAG
ORF-KpnI-R GGTACCGTGCGATCACCGCTTGA
NLSdel-F GCCAGTGAGTTTGGGAAGCCCA
NLSdel-R CTTCCCAAACTCACTGGCGCTGC
NLSmut1-F AGTGAGGCGGCGGCGCAGAAG
NLSmut1-R CTTCTGCGCCGCCGCCTCACT
NLSmut2-F AGTGCGGCGGCCTTTGGGAA
NLSmut2-R TTCCCAAAGGCCGCCGCACT
ORF-F CCATGAATGACCGGAGCA
ORF-R GTGCGATCACCGCTTGAA
50 CCouter AGGCTCCTCGAAGTTTCTCC
50 CCinner CTCATCGTCCTTCATTGTCC
30 CCouter ACTCCCGCCGCTGCTTTCTG
30 CCinner GAGCAAGCTGCTGCTGCCCA
Exon1-F GTCCCCGAGCCGGATTCC
Exon4-R GGCGGAGGACGCAGCCT
a F indicates forward primer, R indicates reverse primer.2.3. Cell culture, transfection and luciferase assay
HeLa cells were grown in a 24-well plate to 80% conﬂuence and
transfected with 0.2 lg of pp53-luc, 0.2 lg of pCMV-b (Clontech)
and increasing amounts of pMyc-CCDC106 (0, 0.1, 0.2, 0.4 lg)
using Lipofectamine 2000 (Invitrogen). At 36 h after transfection,
the cells were lysed to measure luciferase activity using the lucif-
erase assay system (Promega) as previously described [19]. Lucifer-
ase activities were normalized according to b-galactosidase
activities.
2.4. Antibodies
Rabbit polyclonal antibodies to human CCDC106 were raised
using a peptide (2NDRSSRRRTMKDD14C) conjugated to Keyhole
Limpet Hemocyanin (KLH) and puriﬁed by afﬁnity puriﬁcation by
Signalway Antibody Co., Ltd. (Nanjing, China). Rabbit anti-Myc
polyclonal antibody, mouse anti-HA monoclonal antibody, mouse
anti-p53 (Pab 1801) monoclonal antibody, and all the secondary
antibodies for Western blotting or immunoﬂuoresence staining
were purchased from Santa Cruz.
2.5. Subcellular localisation analysis by ﬂuorescence microscopy
HeLa cells were seeded on glass coverslips and treated as de-
scribed previously [20]. To detect the localisation of expressed
EGFP-fusion proteins, HeLa cells were transfected with individual
EGFP-fusion protein expression plasmids. At 24 h post-transfec-
tion, the cells were ﬁxed, and ﬂuorescent signals were revealed un-
der the ﬂuorescence microscope (Axioskop 2, Carl Zeiss). To detect
the localisation of endogenous p53 and CCDC106 protein, cells
were processed and sequentially incubated with primary antibody
and ﬂuorescently labelled secondary antibody as described previ-
ously [20]. The murine anti-p53 monoclonal antibody and Texas
Red-conjugated anti-mouse IgG (red) were used to detect p53,
while rabbit anti-CCDC106 polyclonal antibody and FITC-conju-
gated anti-rabbit IgG (green) were used to detect CCDC106. Nuclei
were stained by Hoechst 33258 (blue).
2.6. siRNA treatment
Three siRNAs designed against different regions of the human
CCDC106 gene were synthesized (#1 forward 50-GUCGGAGGCGG-
ACAAUGAATT-30 and reverse 50-UUCAUUGUCCGCCUCCGACTG-30,
#2 forward 50-GGGAGAGGCAGCGAGUGAATT-30 and reverse 50-
UUCACUCGCUGCCUCUCCCGG-30, #3 forward 50-CGCGUGAGACA-Purpose
CA ORF cloning
A
AGGCCCG Deletion mutagenesis of NLS
CTTCTTC
Point mutagenesis of NLS1
Point mutagenesis of NLS2
ORF ampliﬁcation
50-RACE
50-RACE nested PCR
30-RACE
30-RACE nested PCR
Ampliﬁcation of variants
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Non-sense siRNA (forward 50-UUCUCCGAACGUGUCACGUTT-30 and
reverse 50-ACGUGACACGUUCGGAGAATT-30) was used as negative
control. HeLa cells were transfected with siRNA at a ﬁnal concen-
tration of 100 nmol/L using Lipofectamine 2000 (Invitrogen). At
36 h after transfection, cell lysates were extracted for Western
blotting to assess relative CCDC106 protein level.
2.7. Co-immunoprecipitation (co-IP) and Western blotting
Co-IP and Western blotting were performed as previously
described [20]. Brieﬂy, HeLa cells were transfected with pMyc-
CCDC106 and pHA-p53 plasmids. At 24 h after transfection, cell ly-
sates were prepared and immunoprecipitated with rabbit anti-Myc
polyclonal antibody or preimmune rabbit IgG, and the precipitated
protein was detected by Western blot analysis using the anti-HA
monoclonal antibody.
2.8. Analysis of the inﬂuence of CCDC106 on level and degradation of
p53 protein
To examine the inﬂuence of CCDC106 on the level of p53 pro-
tein, HeLa cells grown on a 6 cm plate were co-transfected with
2 lg of pHA-p53 and increasing amounts of pMyc-CCDC106 (0, 2,
4, 8 lg) and harvested at 8 h post-transfection. To detect the inﬂu-
ence of CCDC106 on the degradation of p53 protein, 2 lg of pHA-
p53 and 4 lg of pMyc-CCDC106 or empty vector pCMV-Myc were
transfected into HeLa cells. At 8 h post-transfection, transfected
cells were incubated with either cycloheximide (CHX, 50 lg/ml)
for different lengths of time (0, 1, 2 and 4 h), or CHX plus increasing
concentrations of MG132 (0, 10, 20, 40 lM) for 1.5 h. Cell lysates
were prepared and separated by 10% SDS–PAGE electrophoresis.
PageRuler™ prestained protein ladder (Fermentas) was used as
molecular weight marker. A single blot membrane was cut into
strips based on molecular weight and incubated with anti-HA,Fig. 1. In vivo identiﬁcation of variant transcripts and protein of CCDC106. (A) RT-PCR ana
(B) Schematic representation of variant transcripts. The exons and introns are shown as b
and the RT primer positions are indicated by arrows. (C) Endogenous CCDC106 protein w
several cell lines and HeLa cells transfected with non-sense siRNA (NC) or CCDC106 siR
rehybridised with anti-GAPDH antibody as loading control.anti-Myc and anti-Actin antibodies to detect the protein levels of
HA-p53, Myc-CCDC106 and b-Actin, respectively.
3. Results and discussion
3.1. Identiﬁcation of three variant transcripts of the CCDC106 gene
The sequence of the CCDC106 gene is available in GenBank
(accession no. NM_013301), but this sequence has not been con-
ﬁrmed experimentally. To validate the sequence of the CCDC106
gene, we ampliﬁed via PCR and sequenced the putative coding se-
quence of CCDC106. Based on the conﬁrmed coding sequence,
gene-speciﬁc primers were then designed and used to extend the
50- and 30-ﬂanking sequences by RLM-RACE. We identiﬁed three
fragments in the 50-RACE reaction and one fragment in the 30-RACE
reaction. After sequencing, the three fragments of 50-ﬂanking se-
quences, the 30-ﬂanking sequence and the coding sequence were
assembled into three different full-length cDNAs, representing
three variant transcripts. The sequence data of these three tran-
scripts were submitted to GenBank with the accession numbers
GU354321, GU354322, GU354323, respectively. BLAST searching
of the human genomic database using the sequences of the three
variant transcripts showed that these three variant transcripts
are transcribed from the same transcript start site, and each con-
sists of six exons, but these transcripts differ in their second exons
due to the use of an alternative splice acceptor site of exon 2
(Fig. 1B). To further conﬁrm the in vivo expression of these three
variant transcripts, we designed primers able to amplify the three
transcripts and performed RT-PCR using HeLa cDNA as template.
As shown in Fig. 1A, the ampliﬁcation produced three different
products: 232 bp, 288 bp and 476 bp, corresponding to variant
transcript 1, 2, and 3, respectively. All these amplicons were fur-
ther conﬁrmed by sequencing.
We next examined the open reading frame (ORF) using ORF Fin-
der (http://www.ncbi.nlm.nih.gov/gorf/gorf.html) and found thatlysis of HeLa RNA that identiﬁes the transcript 1 (232 bp), 2 (288 bp) and 3 (476 bp).
oxes (open boxes for untranslated regions, black boxes for coding regions) and lines,
as determined by Western blotting with rabbit polyclonal anti-CCDC106 antibody in
NA (siRNA-1, siRNA-2, siRNA-3). The same blot membrane was then stripped and
Fig. 2. Mutation of the NLSs abolishes the nuclear localisation of CCDC106. The EGFP-fusion protein expressing plasmids and empty vector pEGFP-C3 were transfected into
HeLa cells, and EGFP ﬂuorescence was examined directly 24 h post-transfection by ﬂuorescence microscopy. Nuclei were stained by Hoechst 33 258. Merge represents the
combined image of EGFP ﬂuorescence and nucleus staining.
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which encodes a protein of 280 amino acids with a calculated
molecular weight of 32 kDa. To conﬁrm this prediction, the rabbit
CCDC106 polyclonal antibody was used for Western blotting to
examine endogenous CCDC106 protein in cell lines. As shown in
Fig. 1C, a band of 32 kDa was detected in lysates of cells, consis-
tent with the predicted size. From the relative intensities of bands
for CCDC106 and GAPDH, we found that CCDC106 was predomi-
nately expressed in cell lines NCI-H 1299, NCI-H292 and SW480,
while reduced expression of CCDC106 was also detected in cell
lines Caco-2, PC3, Du145 and HeLa. To validate the speciﬁcity of
the CCDC106 polyclonal antibody raised by us, three siRNAs
against different regions of the human CCDC106 gene were synthe-Fig. 3. CCDC106 co-localises with and interacts with p53. (A) Colocalisation of endogeno
antibody and Texas Red-conjugated anti-mouse IgG (red) were used to detect p53, whe
(green) were used to detect CCDC106. Nuclei were stained by Hoechst 33258 (blue). Y
CCDC106 (white and open arrows show the localisation during metaphase and anaphase o
p53 by co-IP assay. HeLa cells were transfected with pMyc-CCDC106 and pHA-p53
immunoprecipitated (IP) with rabbit anti-Myc polyclonal antibody or control preimmun
with the anti-HA monoclonal antibody. A total of 50 lg of cell extract was used as posisized and transfected individually into HeLa cells. As shown in
Fig. 1C, all these CCDC106 siRNAs can effectively inhibit CCDC106
expression as determined by the rabbit CCDC106 polyclonal anti-
body, suggesting that the antibody is speciﬁc to CCDC106 protein.
3.2. A bipartite NLS mediates the nuclear localisation of CCDC106
To determine the subcellular localisation of the CCDC106 pro-
tein, we transiently transfected the EGFP-CCDC106 fusion protein
expression plasmid or EGFP empty vector into HeLa cells. The
localisation of the EGFP or EGFP-fusion protein in living cells was
detected by ﬂuorescence microscopy at 24 h post-transfection. As
shown in Fig. 2, EGFP protein was observed in both the cytoplasmus CCDC106 protein and p53 protein in HeLa cells. The murine anti-p53 monoclonal
reas rabbit anti-CCDC106 polyclonal antibody and FITC-conjugated anti-rabbit IgG
ellow in merged image (indicated by arrows) represents colocalisation of p53 and
f cell cycle, respectively). (B) Detection of protein interaction between CCDC106 and
plasmids. At 8 h after transfection, cell extracts (800 lg) were prepared and
e rabbit IgG. Coprecipitating HA-p53 was detected by immunoblotting (IB) analysis
tive control (Input). Marker, prestained protein molecular weight marker.
Fig. 4. Inhibitory effect of CCDC106 expression on p53 transcription activity. HeLa
cells were co-transfected with pp53-luc and increasing amounts of pMyc-CCDC106
as indicated. Luciferase activities were measured 36 h post-transfection. Data
(means ± S.D.) were represented as the fraction of activity relative to that observed
in cells without pMyc-CCDC106.
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exclusively in the nucleus, indicating that CCDC106 is a nuclear
protein. Using the LOCtree software [21], we found that CCDC106
contains two putative NLS (NLS1, 151RRR153 and NLS2, 162RRR164).
To examine this prediction, we made a series of mutants and trans-
fected them into HeLa cells. As shown in Fig. 2, deletion of the
putative NLS (residues 151–164) resulted in cytoplasmic localisa-
tion of CCDC106 and exclusion of CCDC106 from the nucleus. Sub-
stitution of the arginines of both NLS1 and NLS2 with alanines also
led to the exclusive cytoplasmic localisation of CCDC106, whereas
site-directed mutagenesis of only one of both clusters of arginine
residues led to a mixed distribution in both the cytoplasm and
the nucleus, suggesting that the two clusters of basic residues in
the NLS are indispensable for nuclear localisation of CCDC106.
These results show that the region of residues 151–164 in the mid-
dle of CCDC106 is a bipartite NLS that is responsible for the nuclear
localisation of CCDC106.
3.3. CCDC106 co-localises and interacts with p53 in the nucleus
CCDC106 was previously identiﬁed as a p53-binding partner by
high-throughput automated yeast two-hybrid screening [18].
Therefore, we determined whether these two proteins share the
same location in a cell using immunoﬂuorescence staining. Consis-
tent with the localisation of overexpressed EGFP-tagged CCDC106,Fig. 5. CCDC106 promotes the proteasome-dependent degradation of p53 protein. (A) H
CCDC106 (0, 2, 4, 8 lg) and harvested 8 h post-transfection. (B and C) HeLa cells were tra
Myc. At 8 h post-transfection, transfected cells were incubated with either CHX (50 l
concentrations of MG132 (0, 10, 20, 40 lM) for 1.5 h (C). Cell lysates were separated b
membrane was cut into strips and incubated with matched primary antibody as describendogenous CCDC106 protein is localised in the nucleus of HeLa
cells (Fig. 3A). Interestingly, although both CCDC106 and p53 are
predominantly localised in the nucleus, the protein signals are
merged mainly in the mitotic (M) phase of the cell cycle
(Fig. 3A), suggesting that the interaction of CCDC106 and p53 oc-
curs mainly in M phase.
To further conﬁrm the in vivo interaction between CCDC106
and p53, we performed co-immunoprecipitation experiments.
Myc-tagged CCDC106 and HA-tagged p53 expression plasmids
were introduced into HeLa cells. The cell lysates were precipitated
with ether control IgG or anti-Myc polyclonal antibody, and the
precipitated complex was detected for the presence of HA-p53
by western blotting using anti-HA monoclonal antibody. As shown
in Fig. 3B, p53 could be detected in immune complexes precipi-
tated by anti-Myc monoclonal antibody, but not by IgG, indicating
that CCDC106 can interact with p53.
3.4. CCDC106 inhibits the transcriptional activity of p53
The tumour suppressor function of the p53 protein is mainly
correlated with its ability to transcriptionally activate promoters
containing p53-binding sites. Therefore, we studied the effects of
CCDC106 overexpression on the transactivation activity of p53 in
order to determine the functional signiﬁcance of the binding of
CCDC106 to p53. The pp53-TA-luc construct containing a p53 re-
sponse element was transfected into HeLa cells, which express
wild-type p53, together with increasing amounts of the CCDC106
expression plasmid pMyc-CCDC106. We found that transfection
of CCDC106 signiﬁcantly decreased the luciferase activity of
pp53-TA-luc in a dose-dependent manner, suggesting CCDC106
inhibits the transactivation of p53 (Fig. 4).3.5. CCDC106 stimulates p53 protein degradation
To elucidate the mechanism for the inhibited transcription
activity of p53 by CCDC106, we then examined whether CCDC106
affected the level of p53 protein. HeLa cells were co-transfected
with 2 lg of pHA-P53 and increasing amounts of pMyc-CCDC106
(0, 2, 4, 8 lg). The results show that with an increase of Myc-
CCDC106 protein, the level of HA-p53 protein decreased rapidly,
but no change in the level of endogenous b-actin protein was ob-
served (Fig. 5A). These results indicate that CCDC106 decreases
the p53 protein level. To further determine whether the reduced
level of the p53 protein resulted from p53 protein degradation,eLa cells were transfected with 2 lg of pHA-p53 and increasing amounts of pMyc-
nsfected with 2 lg of pHA-p53 and 4 lg of pMyc-CCDC106 or empty vector pCMV-
g/ml) for different lengths of time (0, 1, 2 and 4 h) (B), or CHX plus increasing
y 10% SDS–PAGE electrophoresis and transferred onto a PVDF membrane. The blot
ed in Section 2.
1090 J. Zhou et al. / FEBS Letters 584 (2010) 1085–1090we compared the p53 protein degradation half-lives in HeLa cells
transfected with pMyc-CCDC106 or empty vector pCMV-Myc. As
shown in Fig. 5B, p53 was much more rapidly degraded in cells
transfected with pMyc-CCDC106 than in cells with empty vector.
However, treatment with the proteasomal inhibitor MG132 efﬁ-
ciently rescued the protein level of p53 (Fig. 5C), indicating that
p53 is degraded in an ubiquitin-proteasome-dependent degrada-
tion manner. These results suggest that CCDC106 can increase
the proteasome-dependent degradation of p53.
In conclusion, this study identiﬁed for the ﬁrst time the putative
gene CCDC106 as a functional gene through a series of experi-
ments. We cloned three variant transcripts of the CCDC106 gene
and identiﬁed the in vivo expression of its transcripts and protein
in cancer cell lines. Furthermore, we discovered that CCDC106 is a
novel negative regulator of p53. Loss of p53 function is a character-
istic of almost all human tumours [3]. We found that CCDC106 is
highly expressed in p53 wild-type cancer cell lines NCI-H292 and
HeLa (Fig. 1C), suggesting that the ectopic expression of CCDC106
might contribute to tumourigenesis by blocking p53-mediated
growth suppression and apoptosis. However, other p53 wild-type
cancer cell lines such as HCT116 and MCF-7 express much low
level of CCDC106. In these cell lines, p53 activity is possibly pre-
vented by other cellular factors. For example, BCAS2 gene is up-
regulated by gene ampliﬁcation in breast cancer cell lines MCF-7
[22,23]. BCAS2 protein directly interacts with p53 to reduce p53
transcriptional activity by mildly but consistently decreasing p53
protein [23]. Our studies concerning the activity of CCDC106
should be valuable toward understanding the process of tumouri-
genesis in cancers harbouring wild-type p53.
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